Probity Advisors Inc. Sells 390 Shares of Gilead Sciences, Inc. $GILD

Probity Advisors Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,516 shares of the biopharmaceutical company’s stock after selling 390 shares during the quarter. Probity Advisors Inc.’s holdings in Gilead Sciences were worth $1,499,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in GILD. Brighton Jones LLC increased its position in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $215,000. GAMMA Investing LLC increased its position in shares of Gilead Sciences by 24.9% during the 1st quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company’s stock valued at $2,550,000 after purchasing an additional 4,532 shares during the last quarter. Nilsine Partners LLC bought a new position in shares of Gilead Sciences during the 1st quarter valued at approximately $208,000. Finally, Cambridge Investment Research Advisors Inc. increased its position in shares of Gilead Sciences by 25.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 190,773 shares of the biopharmaceutical company’s stock valued at $21,376,000 after purchasing an additional 38,530 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD stock opened at $123.11 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $85.60 and a twelve month high of $124.11. The stock has a market capitalization of $152.76 billion, a price-to-earnings ratio of 24.52, a P/E/G ratio of 0.84 and a beta of 0.34. The stock has a fifty day simple moving average of $115.27 and a two-hundred day simple moving average of $110.62. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same period in the prior year, the business earned $2.01 EPS. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on GILD shares. Cantor Fitzgerald boosted their target price on Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research report on Friday. Citigroup upped their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Finally, Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective on the stock in a research report on Tuesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $121.14.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares in the company, valued at $66,013,726.98. This represents a 1.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,500 shares of company stock worth $8,281,540. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.